Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination medication containing **ergotamine, caffeine, acetylsalicylic acid (aspirin), and homatropine**. This oral formulation is indicated for the **acute treatment of migraine and cluster headaches**. - **Ergotamine** is an ergot alkaloid that acts as a vasoconstrictor, reducing dilation in cranial blood vessels. - **Caffeine** enhances the absorption and vasoconstrictive effect of ergotamine. - **Acetylsalicylic acid (aspirin)** is a nonsteroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory effects. - **Homatropine** is an anticholinergic agent typically added at very low doses to reduce excessive cholinergic (gastrointestinal and central nervous system) side effects. The combination aims to relieve headache pain through multiple mechanisms: vascular constriction, reduction in neurogenic inflammation, central analgesia, and mitigation of certain side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ergotamine + caffeine + acetylsalicylic acid + homatropine.